mp.weixin.qq.com· 智药邦·· 1 day agoScore55
Matchpoint Therapeutics Closes $150 Million Series B to Advance Covalent Drug Discovery
机器学习+蛋白质组学开发共价药物｜Matchpoint完成1.5亿美元B轮融资
In brief
Matchpoint Therapeutics, a biotechnology company focused on precision covalent drug discovery using machine learning and proteomics, has closed a $150 million Series B financing announced on October 7, 2026. Kanishka Pothula, managing partner at Nextech Invest, and Brian Matesic of Norwest will join the company's board. The funds will support its covalent drug development programmes.
Source: mp.weixin.qq.com · mp.weixin.qq.com